Association of High Expression of Gro beta with Clinical and Pathological Characteristics of Unfavorable Prognosis in Gastrointestinal Stromal Tumors

作者：Zhao, Hui; Zhu, Huijun; Jin, Qin; Zhang, Shu; Wang, Wei; Wang, Defeng^*; Huang, Jianfei

来源：Disease Markers, 2015, 2015: 1-8.

DOI：10.1155/2015/171035

• ADJUVANT THERAPY
• CXC CHEMOKINES
• CANCER GROWTH
• UP-REGULATION
• SURVIVAL
• IMATINIB
• CARCINOMA
• PROLIFERATION
• ACTIVATION
• APOPTOSIS

GRO beta (CXCL2) is a chemokine produced by endotoxin-treated macrophages that mediates inflammation and tumor development. However, little is known about GRO beta expression in gastrointestinal stromal tumors (GIST) or the relationship between GRO beta expression and clinical attributes of GIST. GRO beta expression was examined via immunohistochemical staining of 173 GIST samples using tissue microarray. The relationship between GRO beta expression and relevant patient and tumor characteristics was assessed, using chi-square tests. Univariate and multivariate analysis was carried out using the Cox regression method. High GRO beta cytoplasm staining was detected in 56 (32.4%) specimens; high GRO beta nuclear staining was detected in 64 (37.0%) specimens. High GRO beta cytoplasm staining was significantly associated with patients' age (P = 0.043) and tumor location (P = 0.014), while high GRO beta nucleus staining was significantly associated with mitotic index (P = 0.034), tumor location (P = 0.049), and AFIP-Miettinen risk classification (P = 0.048). Kaplan-Meier survival curves showed GIST patients with low GRO beta cytoplasm expression (P = 0.023) and mitotic index < 6 per 50 HPFs (P = 0.026) to have a more favorable prognosis. These findings indicate that GRO beta expression correlates with malignant GIST phenotypes and could be an unfavorable prognostic marker in patients with GIST.

• 出版日期2015
• 单位南通大学